Greenland Mines Ltd (GRML)
| Market Cap | 31.89M +320.5% |
| Revenue (ttm) | n/a |
| Net Income | -11.29M |
| EPS | -0.30 |
| Shares Out | 108.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,778,665 |
| Open | 0.2942 |
| Previous Close | 0.2988 |
| Day's Range | 0.2740 - 0.3000 |
| 52-Week Range | 0.1135 - 3.9100 |
| Beta | 2.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About GRML
Greenland Mines Ltd operates as a natural resources company. It focuses on the exploration and development of Skaergaard Project in Southeast Greenland. The company is also involved in the development of KLTO-202, a cell and gene therapy for amyotrophic lateral sclerosis. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.
Financial Performance
Financial StatementsNews
Greenland Mines Secures Icebreaker Argus For 2026 Skaergaard Field Program
Ice-class vessel deployment strengthens Arctic logistics infrastructure and enables efficient execution of the 2026 Skaergaard field program CHARLOTTE, N.C., March 25, 2026 /PRNewswire/ -- Greenland M...
Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance
Extension reflects Company's continued compliance with all other applicable Nasdaq listing requirements CHARLOTTE, N.C., March 23, 2026 /PRNewswire/ -- Greenland Mines Ltd (Nasdaq: GRML) ("Greenland M...
Greenland Mines Engages WSP Denmark to Launch Comprehensive Environmental Baseline Program at Skaergaard Mining Site
Engagement supports exploitation license pathway while advancing responsible, large-scale development of the Skaergaard Project CHARLOTTE, N.C., March 19, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Gr...
Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neuro...
KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR
Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company ...
Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offerings NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the Company)...
Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for com...
Klotho Neurosciences to Present at the Biotech Showcase 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company"), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting...
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth ...
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
NEW YORK , Oct. 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") a U.S.-based biogenetics company, announces that members of its leadership team will atte...
Klotho Neurosciences Announces Expiration of Letter of Intent
NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") today announced that its Letter of Intent with Turn Biotechnologies was allowed to expire ...
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
NEW YORK and PALO ALTO, Calif. , Sept. 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire s...
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseas...
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics NEW YORK , Aug. 18, 2025 /PRNewswire...
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy ...
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO...
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company"...
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
NEW YORK , July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech r...
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK , July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company foc...
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
NEW YORK , July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, toda...
This Penny Stock Exploded 500% In June: What You Need To Know
Shares of the anti-aging biogenetics company Klotho Neurosciences, Inc. KLTO are on retail investors' radars after the stock exploded by more than 500% in June. Here's a look at recent catalysts that ...
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK , June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical...
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
NEW YORK , June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, includi...
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
Key highlights of the announcement include: Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90%...
KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT
Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant ex...